Skip to content
10-K

Annual Report

TVARDI THERAPEUTICS, INC. TVRD

0001104659-26-037729

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 26, 2026 9.38M sh
Shares Diluted FY 2025 · Dec 31, 2025 7.78M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 2.57M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$23.5M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$18.31M
Short Term Investments FY 2025 · Dec 31, 2025 $10.08M
Cash And Equivalents FY 2025 · Dec 31, 2025 $20.73M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $31.61M
Stockholders Equity FY 2025 · Dec 31, 2025 $20.95M
Stockholders Equity restated FY 2025 · Dec 31, 2024 −$91.13M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$62.06M
Current Liabilities FY 2025 · Dec 31, 2025 $11.04M
Current Liabilities restated FY 2025 · Dec 31, 2024 $10.37M
Total Liabilities FY 2025 · Dec 31, 2025 $11.13M
Total Liabilities restated FY 2025 · Dec 31, 2024 $40.83M
Current Assets FY 2025 · Dec 31, 2025 $31.54M
Current Assets restated FY 2025 · Dec 31, 2024 $31.69M
Total Assets FY 2025 · Dec 31, 2025 $32.07M
Total Assets restated FY 2025 · Dec 31, 2024 $35.2M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.26
Eps Diluted restated FY 2025 · Dec 31, 2024 −$11.42
Eps Basic FY 2025 · Dec 31, 2025 −$2.46
Eps Basic restated FY 2025 · Dec 31, 2024 −$11.42
Sga Expense FY 2025 · Dec 31, 2025 $8.74M
Sga Expense restated FY 2025 · Dec 31, 2024 $4.46M
Rd Expense FY 2025 · Dec 31, 2025 $18.01M
Rd Expense restated FY 2025 · Dec 31, 2024 $23.65M
Net Income FY 2025 · Dec 31, 2025 −$18.21M
Net Income restated FY 2025 · Dec 31, 2024 −$29.4M
Operating Income FY 2025 · Dec 31, 2025 −$26.75M
Operating Income restated FY 2025 · Dec 31, 2024 −$28.11M